Gregory A. Demopulos, MD
Known title: Chairman, CEO & PresidentCIK: 0001472160
Gregory A. Demopulos, MD's purchase track record
Gregory A. Demopulos, MD has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/17/2023 | OMER | $25K | +198.2% | +110.4% | +17.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| OMER | ▲ Buy | Option Exercise | 400,000 | $4.1M | 2/18/2026 | View on chart |
| OMER | ▼ Sell | Tax Withholding | 357,678 | $4.3M | 2/18/2026 | View on chart |
| OMER | ▼ Sell | Gift | 600,000 | $0 | 10/13/2025 | View on chart |
| OMER | ▼ Sell | Gift | 300,000 | $0 | 10/13/2025 | View on chart |
| OMER | ▼ Sell | Gift | 300,000 | $0 | 10/13/2025 | View on chart |
| OMER | ▲ Buy | Open Market | 15,000 | $25K | 11/17/2023 | View on chart |
| OMER | ▲ Buy | Grant | 25,000 | $36K | 11/14/2023 | View on chart |
| OMER | ▲ Buy | Grant | 37,500 | $48K | 11/13/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
OMER Shares Fall After European Regulatory Setback
Omeros shares dropped after the Committee for Medicinal Products for Human Use (CHMP) again gave a negative opinion on the drug Narsoplimab. The decision was confirmed by European regulators, marking a second rejection and pushing the stock below its $9.96 support level for the first time in almost three months. The drop comes as the stock shows a moderate RSI of 40.2 and recent volume spikes, indicating increased selling pressure.
OMER Shares Fall After European Regulatory Setback. Omeros shares dropped after the Committee for Medicinal Products for Human Use (CHMP) again gave a negative opinion on the drug Narsoplimab. The decision was confirmed by European regulators, marking a second rejection and pushing the stock below its $9.96 support level for the first time in almost three months. The drop comes as the stock shows a moderate RSI of 40.2 and recent volume spikes, indicating increased selling pressure.